William Blair Has Negative Estimate for LENZ Q1 Earnings

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Research analysts at William Blair decreased their Q1 2025 earnings per share (EPS) estimates for shares of LENZ Therapeutics in a note issued to investors on Thursday, March 20th. William Blair analyst L. Hanbury-Brown now anticipates that the company will earn ($0.56) per share for the quarter, down from their previous forecast of ($0.48). The consensus estimate for LENZ Therapeutics’ current full-year earnings is ($2.18) per share. William Blair also issued estimates for LENZ Therapeutics’ Q3 2025 earnings at ($0.74) EPS, Q4 2025 earnings at ($0.98) EPS, FY2025 earnings at ($2.97) EPS, Q1 2026 earnings at ($0.92) EPS, Q2 2026 earnings at ($0.77) EPS, Q3 2026 earnings at ($0.67) EPS and Q4 2026 earnings at ($0.53) EPS.

LENZ has been the subject of several other reports. TD Cowen started coverage on LENZ Therapeutics in a research report on Tuesday, March 18th. They issued a “buy” rating and a $60.00 price objective for the company. Citigroup boosted their price objective on shares of LENZ Therapeutics from $44.00 to $47.00 and gave the company a “buy” rating in a report on Thursday, March 20th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $41.67.

LENZ Therapeutics Price Performance

NASDAQ:LENZ opened at $26.43 on Monday. The company’s 50-day moving average is $24.30 and its two-hundred day moving average is $27.12. The firm has a market capitalization of $726.85 million, a price-to-earnings ratio of -5.54 and a beta of 0.58. LENZ Therapeutics has a 1-year low of $14.42 and a 1-year high of $38.93.

LENZ Therapeutics (NASDAQ:LENZ) last announced its quarterly earnings data on Wednesday, March 19th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.04).

Institutional Investors Weigh In On LENZ Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. acquired a new position in LENZ Therapeutics in the 4th quarter valued at about $29,000. KLP Kapitalforvaltning AS acquired a new position in shares of LENZ Therapeutics in the fourth quarter valued at approximately $46,000. Tower Research Capital LLC TRC grew its holdings in shares of LENZ Therapeutics by 162.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 1,860 shares of the company’s stock valued at $54,000 after purchasing an additional 1,151 shares in the last quarter. Virtus ETF Advisers LLC purchased a new stake in LENZ Therapeutics during the 4th quarter worth approximately $67,000. Finally, SG Americas Securities LLC lifted its holdings in LENZ Therapeutics by 20.7% during the 4th quarter. SG Americas Securities LLC now owns 5,458 shares of the company’s stock worth $158,000 after buying an additional 935 shares in the last quarter. Hedge funds and other institutional investors own 54.32% of the company’s stock.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.